Accessibility and accommodation Novartis is committed to working with and providing reasonable accommodation to individuals with disabilities. If, because of a medical condition or disability, you ...

主要职责：保证每月拜访规定数量的目标客户和组织产品学术推广会，配合公司大型学术活动建立完善的客户管理体系，提高客户服务质量及时、准确执行报告系统，及时汇报工作的进展，及时反馈市场信息配合地区经理的协同拜访完成地区经理或者大区经理指派的工作任务积极参与和推进合规项目 ...

Sie suchen Kreativität und Innovation? Novartis bietet Ihnen das nötige Umfeld! Menschen, die uns mit ihrem Können und ihrer Erfahrung weiterbringen, können das Gleiche auch von uns erwarten. Think ...

Offene Stellen Rund 3.300 Mitarbeitende setzen sich bei Novartis Österreich gemeinsam dafür ein, das Leben von Patientinnen und Patienten zu verlängern und zu verbessern. Willst du dabei sein? Dann ...

Zaposlitev v Novartisu v Sloveniji V Novartisu spodbujamo inovativnost in razvoj ter delujemo na številnih področjih. Tudi vi lahko postanete del tega, del naše zgodbe. Pridružite se naši ustvarjalni ...

Audit & Finance BD&L & Strategic Planning Commercial & General Management Communications & Public Affairs Data and Digital Facilities & Administration Human Resources Information Technology ...

V Novartisu přetváříme medicínu Jsme globální farmaceutickou společností, která působí ve 140 zemích světa a zaměstnává přibližně 110 tisíc lidí. Naším posláním je objevovat nová řešení, které ...

Novartis works with the patient community around the world to discover new ways to improve and extend people’s lives. Novartis works closely with healthcare professionals around the world to support ...

Modern Slavery Statement 2024 - Australia, Canada, and United Kingdom (PDF 0.3 MB) Our statement under UK, Canadian and Australian legislation on our efforts to address modern slavery. Norwegian ...

Product portfolio At Novartis, we reimagine medicine to improve and extend people’s lives. This includes discovering and developing breakthrough therapies and finding new ways to deliver these ...

The purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel (administered once following lymphodepletion) versus Standard of Care (SOC) in patients with systemic lupus ...

This is a Phase 3, parallel group, placebo-controlled, double-blind, confirmatory study in patients with CINDU, with an optional Open-label Extension (OLE). The purpose of the core period (52 weeks of ...